Spiramycine Métronidazole Sandoz

Spiramycine Métronidazole Sandoz may be available in the countries listed below.

Ingredient matches for Spiramycine Métronidazole Sandoz

Metronidazole

Metronidazole is reported as an ingredient of Spiramycine Métronidazole Sandoz in the following countries:

• France

Spiramycin

Spiramycin is reported as an ingredient of Spiramycine Métronidazole Sandoz in the following countries:

• France

International Drug Name Search

Domperidona Ciclum

Domperidona Ciclum may be available in the countries listed below.

Ingredient matches for Domperidona Ciclum

Domperidone

Domperidone is reported as an ingredient of Domperidona Ciclum in the following countries:

• Portugal

International Drug Name Search

Sultopride Panpharma

Sultopride Panpharma may be available in the countries listed below.

Ingredient matches for Sultopride Panpharma

Sultopride

Sultopride hydrochloride (a derivative of Sultopride) is reported as an ingredient of Sultopride Panpharma in the following countries:

• France

International Drug Name Search

SPMC Salbutamol

SPMC Salbutamol may be available in the countries listed below.

Ingredient matches for SPMC Salbutamol

Salbutamol

Salbutamol is reported as an ingredient of SPMC Salbutamol in the following countries:

• Sri Lanka

International Drug Name Search

Amiplin

Amiplin may be available in the countries listed below.

Ingredient matches for Amiplin

Amitriptyline

Amitriptyline hydrochloride (a derivative of Amitriptyline) is reported as an ingredient of Amiplin in the following countries:

• Japan

International Drug Name Search

Natazia

Natazia is a brand name of dienogest/estradiol, approved by the FDA in the following formulation(s):

NATAZIA (dienogest; estradiol valerate - tablet; oral-28)

• 
  Manufacturer: BAYER HLTHCARE
  
  Approval date: May 6, 2010
  
  Strength(s): N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1MG,N/A ^[RLD]

Has a generic version of Natazia been approved?

No. There is currently no therapeutically equivalent version of Natazia available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Natazia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Combination compound for contraception based on natural estrogen
  Patent 6,133,251
  Issued: October 17, 2000
  Inventor(s): Dittgen; Michael & Fricke; Sabine & Hoffmann; Herbert & Moore; Claudia & Oettel; Michael & Ostertag; Monika
  Assignee(s): Jenapharm GmbH & Co. KG
  The combination preparation for contraception includes a first stage of 2 to 4 first stage daily dosage portions, a second stage of two groups of second stage daily dosage portions, a third stage of 2 to 4 third stage daily dosage portions and an additional stage of 2 to 4 additional stage daily dosage portions. The first stage daily dosage portion is an effective amount of natural estrogen, the second stage daily dosage portion is an effective amount of a combination of natural estrogen and natural or synthetic gestogen, the third stage daily dosage portion is another effective amount of natural estrogen and an additional stage daily dosage portion consists of a placebo. The first group of the second stage consists of 3 to 5 daily dosage portions and the second group, 13 to 17 daily dosage portions. More of the gestogen is included in the effective amount in the second group of the second stage than in the first group. The effective amount of the natural estrogen is constant in both the first and third stages, but smaller in the third stage than in the first stage.
  
  Patent expiration dates:
  
  
  • October 25, 2016
    
    ✓ 
    Patent use: PREVENTION OF PREGNANCY
    ✓ 
    Drug product
    ✓ 
    Sponsor has requested patent be delisted
  
  
  
  • October 25, 2016
    
    ✓ 
    Patent use: CONTRACEPTION
    ✓ 
    Drug product
    ✓ 
    Sponsor has requested patent be delisted
  
  
  
  • October 25, 2016
    
    ✓ 
    Patent use: PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
    ✓ 
    Drug product
    ✓ 
    Sponsor has requested patent be delisted
  
  



• 
  Combination preparation for contraception based on natural estrogens
  Patent 6,884,793
  Issued: April 26, 2005
  Inventor(s): Dittgen; Michael & Fricke; Sabine & Hoffmann; Herbert & Moore; Claudia & Oettel; Michael & Ostertag; Monika
  Assignee(s): Jenapharm GmbH & Co. KG
  The combination preparation for contraception includes from 2 to 4 first stage daily dosage portions each including an effective amount of at least one natural estrogen as sole active ingredient, from 16 to 22 second stage daily dosage portions each including an effective amount of a combination of at least one natural estrogen and at least one natural or synthetic gestogen as active ingredient; from 2 to 4 third stage daily dosage portions each including an effective amount of at least one natural estrogen as sole active ingredient; and from 2 to 4 final stage daily dosage portions containing a pharmaceutically acceptable placebo. The estrogen may be estradiol, an estradiol compound that is metabolized to estradiol when taken into the body, a conjugated equine estrogen or a phytoestrogen. The natural or synthetic gestogen can be natural progesterone or a synthetic gestogens, such as medroxyprogesterone acetate.
  
  Patent expiration dates:
  
  
  • October 25, 2016
    
    ✓ 
    Drug product
    ✓ 
    Sponsor has requested patent be delisted
  
  



• 
  Multi-phase contraceptive preparation based on a natural estrogen
  Patent 8,071,577
  Issued: December 6, 2011
  Inventor(s): Endrikat; Jan & Duesterberg; Bernd
  Assignee(s): Bayer Pharma Aktiengesellschaft
  The multiphase preparation having higher contraceptive safety and reduced side effects is based on a combination of a natural oestrogen with dienogest or drospirenone. The multiphase preparation is characterized by a first phase consisting of 2 daily dose units of 3 mg of oestradiol valerate, a second phase consisting of 2 groups of daily dose units, wherein a first group is formed by 5 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least two or three times an ovulation-inhibitory dose of dienogest or drospirenone and a second group is formed by 17 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least three or four times the ovulation-inhibitory dose of dienogest or drospirenone, a third phase consisting of 2 daily dose units of 1 mg of oestradiol valerate, and a further phase consisting of 2 daily dose units of pharmaceutically acceptable placebo.
  
  Patent expiration dates:
  
  
  • May 13, 2026
    
    ✓ 
    Patent use: PREVENTION OF PREGNANCY
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 6, 2013 - NEW PRODUCT
  
  

See also...

• Natazia Consumer Information (Drugs.com)
• Natazia Consumer Information (Wolters Kluwer)
• Natazia Consumer Information (Cerner Multum)
• Natazia Advanced Consumer Information (Micromedex)
• Estradiol Valerate/Dienogest Consumer Information (Wolters Kluwer)
• Dienogest and estradiol Consumer Information (Cerner Multum)
• Estradiol and dienogest Advanced Consumer Information (Micromedex)
• Estradiol valerate and dienogest Advanced Consumer Information (Micromedex)

Ambroxolum

Ambroxolum may be available in the countries listed below.

Ingredient matches for Ambroxolum

Ambroxol

Ambroxol hydrochloride (a derivative of Ambroxol) is reported as an ingredient of Ambroxolum in the following countries:

• Latvia

International Drug Name Search

DTM

DTM may be available in the countries listed below.

Ingredient matches for DTM

Diltiazem

Diltiazem is reported as an ingredient of DTM in the following countries:

• India

International Drug Name Search

Sucraid

Sucraid is a brand name of sacrosidase, approved by the FDA in the following formulation(s):

SUCRAID (sacrosidase - solution; oral)

• 
  Manufacturer: QOL MEDCL
  
  Approval date: April 9, 1998
  
  Strength(s): 8,500 IU/ML ^[RLD]

Has a generic version of Sucraid been approved?

No. There is currently no therapeutically equivalent version of Sucraid available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sucraid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Sucraid.

See also...

• Sucraid Consumer Information (Wolters Kluwer)
• Sucraid Consumer Information (Cerner Multum)
• Sucraid Advanced Consumer Information (Micromedex)
• Sucraid AHFS DI Monographs (ASHP)
• Sacrosidase Consumer Information (Wolters Kluwer)
• Sacrosidase Consumer Information (Cerner Multum)
• Sacrosidase Advanced Consumer Information (Micromedex)
• Sacrosidase AHFS DI Monographs (ASHP)

Kardegic

Kardegic may be available in the countries listed below.

Ingredient matches for Kardegic

Aspirin

Acetylsalicylic Acid lysine (a derivative of Acetylsalicylic Acid) is reported as an ingredient of Kardegic in the following countries:

• Czech Republic


• France


• Hungary


• Mexico

International Drug Name Search

Aclotine

Aclotine may be available in the countries listed below.

Ingredient matches for Aclotine

Antithrombin Iii

Antithrombin III is reported as an ingredient of Aclotine in the following countries:

• France

International Drug Name Search

Devitol

Devitol may be available in the countries listed below.

Ingredient matches for Devitol

Ergocalciferol

Ergocalciferol is reported as an ingredient of Devitol in the following countries:

• Finland

International Drug Name Search